Business
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – Virtual investor webcast today at 8:00 a.m. EDT – CUPERTINO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Reviva Pharmaceuticals","displaySize":"","headline":null,"caption":"Reviva Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D8sDX1mL7wV8j6M4A9rWcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8","width":300,"height":138}},"lazy":false},{"type":"text","content":"– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms –","length":111,"tagName":"p"},{"type":"text","content":"– Generally well-tolerated with low rates of adverse events and discontinuation –","length":81,"tagName":"p"},{"type":"text","content":"– Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects –","length":116,"tagName":"p"},{"type":"text","content":"– Virtual investor webcast today at 8:00 a.m. EDT –","length":51,"tagName":"p"},{"type":"text","content":"CUPERTINO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced a positive full dataset and successful completion of the Company’s Phase 3 RECOVER open-label extension (OLE) 1-year study evaluating the long-term safety, tolerability and efficacy of brilaroxazine in patients with schizophrenia. Once daily brilaroxazine led to robust broad-spectrum efficacy that was sustained over 1-year and was generally well tolerated with a discontinuation rate of 35% in this long-term study. Brilaroxazine is a novel serotonin dopamine signaling modulator with multi-faceted direct and indirect activities on critical pathways implicated in schizophrenia. To register for the virtual investor webcast being held today, June 2, 2025 at 8:00 a.m. EDT regarding the OLE trial data, please visit https://lifescievents.com/event/h4p8mx9cj0w/.","length":1125,"tagName":"p"},{"type":"text","content":"“We are pleased to complete the positive registrational trial for our b...